Grant✓ Small businesses may apply
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
National Institutes of Health
- Opportunity #
- PAR-25-026
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.840, 93.233, 93.839, 93.837, 93.838
- Status
- posted
- Posted
- Dec 5, 2024
- Closes
- Jan 7, 2027
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •County governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Public and State controlled institutions of higher education
- •City or township governments
- •Small businesses
- •For profit organizations other than small businesses
- •Native American tribal governments (Federally recognized)
- •Public housing authorities/Indian housing authorities
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Private institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Independent school districts
- •Special district governments
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •State governments
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Contact
National Institutes of Health · grantsinfo@nih.gov